RECORDATI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.86 EUR | +0.24% |
|
+0.89% | +2.11% |
| Apr. 18 | Futures bullish; car registrations drop | AN |
| Apr. 17 | Mib rebounds as banks boost | AN |
| Sales 2024 * | 2.3B 2.45B | Sales 2025 * | 2.44B 2.59B | Capitalization | 10.26B 10.93B |
|---|---|---|---|---|---|
| Net income 2024 * | 481M 512M | Net income 2025 * | 530M 565M | EV / Sales 2024 * | 5.03 x |
| Net Debt 2024 * | 1.3B 1.39B | Net Debt 2025 * | 1.07B 1.14B | EV / Sales 2025 * | 4.65 x |
| P/E ratio 2024 * |
22.1
x | P/E ratio 2025 * |
19.8
x | Employees | 4,455 |
| Yield 2024 * |
2.86% | Yield 2025 * |
3.15% | Free-Float | 46.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Recordati
More press releases
More news
| 1 day | +0.24% | ||
| 1 week | +1.55% | ||
| Current month | -2.69% | ||
| 1 month | -3.86% | ||
| 3 months | +0.14% | ||
| 6 months | +13.29% | ||
| Current year | +2.11% |
1 week
48.62
50.10
1 month
48.5452.50
Current year
47.2953.38
1 year
39.6553.38
3 years
34.5257.90
5 years
28.2657.90
10 years
11.1257.90
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
Luigi la Corte
DFI | Director of Finance/CFO | 54 | 19-10-31 |
Andrea Recordati
CHM | Chairman | 52 | 98-04-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cathrin Petty
BRD | Director/Board Member | 50 | 18-06-11 |
Giampiero Mazza
BRD | Director/Board Member | 54 | 18-06-11 |
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.52% | 5 M€ | +12.55% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 49.86 | +0.24% | 252,235 |
| 24-04-18 | 49.74 | +1.63% | 226,309 |
| 24-04-17 | 48.94 | -0.81% | 217,036 |
| 24-04-16 | 49.34 | -1.28% | 197,581 |
| 24-04-15 | 49.98 | +1.13% | 172,107 |
Real-time Borsa Italiana, April 19, 2024 at 11:44 am EDT
More quotes
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
49.86
EUR
Average target price
50.84
EUR
Spread / Average Target
+1.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.11% | 10.92B | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
- Stock Market
- Equities
- REC Stock
